ABT 165Alternative Names: ABT-165
Latest Information Update: 06 May 2016
At a glance
- Originator AbbVie
- Class Antineoplastics; Immunoglobulins
- Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours